Clinical Trial Update: A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 study of VX-509 (decernotinib), a JAK3 inhibitor, in active rheumatoid arthritis, including an MRI study and arthroscopic biopsy substudy, has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VX-509

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED